Biopharmaceutical company Coeptis Therapeutics Inc (OTC PINK: COEP) revealed on Wednesday that it has entered into an exclusive licence agreement with the University of Pittsburgh for the rights to SNAP-CAR, a chimeric antigen receptor T cell (CAR T) technology designed to target multiple antigens simultaneously.

The company said SNAP-CAR has the potential to address a range of haematologic and solid tumours, including breast and ovarian cancer. Completion of the exclusive licence deal for SNAP-CAR follows Coeptis' entry into an option agreement with the University of Pittsburgh announced in May 2022.

Jason Lohmueller, PhD, Assistant Professor of Surgery and Immunology in the Division of Surgical Oncology Research at the University of Pittsburgh, stated: "SNAP-CAR T cells can be engineered to address numerous cancers, including solid tumours, while providing researchers with the ability to rapidly screen multiple antibody candidates without the need to generate individual receptors."

Alex Deiters, PhD, Professor of Chemistry at the University of Pittsburgh, said: "Additionally, SNAP-CAR may offer the potential to mitigate the toxicity of CAR T therapy by allowing clinicians to control the adaptor dose. Further, the ability to combine SNAP-CAR T cells with antibodies targeting multiple antigens offers the potential to reduce the likelihood of cancer relapse."